Biography/Disclosures
Biography: Singh is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Associate Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic.
December 30, 2019
1 min read
Save

BLOG: Should we use steroids as an adjuvant to epiretinal membrane peeling?

Biography/Disclosures
Biography: Singh is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Associate Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

When there is significant visual impairment, epiretinal membranes are treated by pars plana vitrectomy and epiretinal membrane peeling.

First performed by Machemer in 1978, the surgery has recently evolved to include the use of certain pharmacologic agents to assist with the surgery.

For example, triamcinolone acetonide (TA), an anti-inflammatory agent used to treat various inflammatory ocular diseases, has been used for visualization of the vitreous during PPV and for staining of the epiretinal membrane prior to peeling. Additionally, TA has been shown to facilitate fluid absorption from the edematous retinal tissue by both stimulating endogenous adenosine signaling in Müller cells and by downregulating vascular endothelial growth factor production. This suggests that the use of TA could be beneficial in the postoperative period for resolving macular edema and suppressing immune response, preventing the re-proliferation of the membrane. One case series nonrandomized study noted that overall, intravitreal TA-assisted vitrectomy patients had a lower incidence of reoperation compared to those without TA administration.

In our pilot study published prior, we evaluated patients treated with intravitreal TA at the end of epiretinal membrane surgery. Visual acuity 3 months after operation was improved in both groups of patients receiving intravitreal injection of TA and control group (P = .001 for the TA and P = .002 for control). However, there was no statistically significant difference in final visual acuity between groups.

In addition, there are known risks associated with intravitreal TA administration. Previous reports have shown that complications include secondary ocular hypertension, development of cataract and increase in intraocular pressure postoperatively. And, most recently, Sisk and colleagues report a series of patients who develop a triad of sterile endophthalmitis, atrophic retinal breaks under the depot intravitreal TA in the inferior retina and rhegmatogenous retinal detachment. All retinal detachment surgeries required silicone oil tamponade. Poor visual outcome at 6 months was common for eyes requiring PPV for retinal detachment repair.

Learn more by following the link to the article here: https://www.healio.com/ophthalmology/journals/osli/2019-10-50-10/%7B63e94139-3f8d-4045-aa76-7c629a31152c%7D/erosive-retinopathy-and-retinal-detachment-from-depot-intravitreal-triamcinolone-acetonide-injection-at-the-end-of-pars-plana-vitrectomy#divReadThis

Like what you are reading? Follow me on Instagram, Facebook and Twitter @drrishisingh.

 

Reference:

Enaida H, et al. Retina. 2004;doi:10.1097/00006982-200312000-00003.

Disclosure: Singh reports he is a consultant to Zeiss, Novartis, Regeneron, Genentech and Alcon and receives grant support from Apellis and Graybug.